Login
E-mail
Password
Mostra password
Ricorda
Password dimenticata?
Iscriviti gratuitamente
Registrazione
Registrazione
Parametri
Parametri
Quotazioni dinamiche 
OFFON
  1. Home
  2. Azioni
  3. Stati Uniti
  4. Nasdaq
  5. Epizyme, Inc.
  6. Notizie
  7. Altre lingue
    EPZM   US29428V1044

EPIZYME, INC.

(EPZM)
Prezzo in differita. Tempo differito Nasdaq - 15/10 22:00:00
4.95 USD   -1.20%
10/08EPIZYME, INC.: rating Sell secondo Morgan Stanley
MM
07/05EPIZYME, INC.: SVB Leerink consiglia Buy
MM
31/03EPIZYME, INC.: Credit Suisse ottimista sul caso
MM
RiassuntoQuotazioniGraficiNotizieRatingAgendaSocietąFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su EPIZYME, INC.
08/10EPIZYME: Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
07/10EPIZYME: Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15/09EPIZYME: Announces Data from TAZVERIK (Tazemetostat) Clinical Programs to be Presented Du..
14/09EPIZYME: Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented D..
23/08EPIZYME: Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
20/08EPIZYME: Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/08EPIZYME: FIFTH AMENDMENT TO LEASE (Form 8-K)
16/08EPIZYME, INC.: Entry into a Material Definitive Agreement, Financial Statements and Exhib..
09/08EPIZYME: Management's Discussion and Analysis of Financial Condition and Results of Opera..
09/08EPIZYME: and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVE..
09/08EPIZYME: Q2 Loss Widens, Revenue Rises; Company Names Grant Bogle as New CEO - Shares Dec..
09/08EPIZYME, INC.: Entry into a Material Definitive Agreement, Results of Operations and Fina..
09/08EPIZYME: Q2 Earnings Snapshot
09/08EPIZYME: Announces CEO Succession
09/08Epizyme, Inc. Announces Management Changes
09/08EPIZYME: Earnings Flash (EPZM) EPIZYME Posts Q2 Revenue $13M
09/08EPIZYME: Reports Second Quarter 2021 Financial Results and Provides Business Update
09/08Epizyme, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
09/08HUTCHMED CHINA: To Develop, Commercialize Epizyme's Tazverik In Greater China
09/08HUTCHMED CHINA: Secures Licensing Rights to Epizyme's Cancer Drug in Greater China
09/08HUTCHMED CHINA: Epizyme Enter Development, Commercialization Deal For Cancer Drug In Chin..
09/08HUTCHMED Limited and Epizyme, Inc. Announces Strategic Collaboration to Develop and Com..
03/08EPIZYME: Announces Date of Second Quarter 2021 Financial Results
29/06TURNING POINT THERAPEUTICS: Names New Chief Financial Officer
28/06EPIZYME, INC.: Change in Directors or Principal Officers (form 8-K)
28/06Epizyme, Inc. Announces Resignation of Paolo Tombesi as the Chief Financial Officer Eff..
28/06Epizyme, Inc. Announces That Matthew E. Ros Will Serve as Principal Financial Officer, ..
25/06EPIZYME, INC.(NASDAQGS: EPZM) dropped from Russell 3000 Value Index
25/06EPIZYME, INC.(NASDAQGS: EPZM) added to Russell 3000E Growth Index
25/06EPIZYME, INC.(NASDAQGS: EPZM) added to Russell Microcap Growth Index
25/06EPIZYME, INC.(NASDAQGS: EPZM) dropped from Russell 3000E Value Index
25/06EPIZYME, INC.(NASDAQGS: EPZM) added to Russell Microcap Index
25/06EPIZYME, INC.(NASDAQGS: EPZM) dropped from Russell 2500 Value Index
25/06EPIZYME, INC.(NASDAQGS: EPZM) dropped from Russell Small Cap Comp Value Index
25/06EPIZYME, INC.(NASDAQGS: EPZM) dropped from Russell 2000 Value Index
25/06EPIZYME, INC.(NASDAQGS: EPZM) added to Russell 3000E Index
24/06EISAI: ANTICANCER AGENT 'TAZVERIK TABLETS 200mg' APPROVED IN JAPAN FOR EZH2 GENE MUTATION..
16/06EPIZYME: Launches EZH2Now Testing Program With Quest Diagnostics
16/06EPIZYME, INC.: Submission of Matters to a Vote of Security Holders (form 8-K)
16/06EPIZYME: Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refracto..
25/05EPIZYME: to Participate in Jefferies Virtual Healthcare Conference
12/05EPIZYME: Announces Preclinical and Clinical Data to be Presented in Oral and Poster Sessi..
06/05EPIZYME: Management's Discussion and Analysis of Financial Condition and Results of Opera..
06/05EPIZYME, INC.: Results of Operations and Financial Condition, Financial Statements and Ex..
06/05EPIZYME: Q1 Earnings Snapshot
06/05EPIZYME: Earnings Flash (EPZM) EPIZYME Posts Q1 Revenue $7.6M
06/05EPIZYME: Provides Business Update and Reports First Quarter 2021 Financial Results
06/05Epizyme, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
29/04EPIZYME: Announces Date of First Quarter 2021 Financial Results
29/03INSIDER TRENDS: Insider Purchase Continues Epizyme Positive Trend
09/03EPIZYME: Barclays Conference Presentation - March 2021
03/03EPIZYME: Cowen Conference Presentation - March 2021
02/03EPIZYME: Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Prioritie..
02/03Epizyme, Inc. Outlines Clinical Progress, Tazverik Development Strategy and Pipeline Pr..
24/02EPIZYME: Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial..
24/02EPIZYME: to Host Strategic Vision Call on March 2, 2021
23/02EPIZYME: Results of Operations and Financial Condition, Financial Statements and Exhibits..
23/02Epizyme, Inc. Provides Update on Clinical Trials
23/02SECTOR UPDATE: Health Care Stocks Decline Premarket Tuesday
23/02EPIZYME: Q4 Net Loss Widens, Revenue Rises; Shares Fall Pre-Bell
23/02EPIZYME: Management's Discussion and Analysis of Financial Condition and Results of Opera..
23/02EPIZYME, INC.: Results of Operations and Financial Condition, Financial Statements and Ex..
23/02EPIZYME: 4Q Earnings Snapshot
23/02EPIZYME: Earnings Flash (EPZM) EPIZYME Reports Q4 Revenue $8.4M
23/02EPIZYME: CORRECTING and REPLACING Epizyme Provides Business Update and Reports Fourth Qua..
23/02Epizyme, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020
23/02Epizyme, Inc. Promotes Dr. Shefali Agarwal to Executive Vice President and Chief Medica..
16/02EPIZYME: Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Partic..
2020EPIZYME: Boehringer Ingelheim Scraps Collaboration Deal With Epizyme
2020EPIZYME, INC.: Termination of a Material Definitive Agreement (form 8-K)
2020EPIZYME: to Participate in Jefferies Virtual London Healthcare Conference
2020EPIZYME: Reports Business Progress and Third Quarter 2020 Financial Results
2020EPIZYME: Announces Expanded Loan Facility with Pharmakon Advisors for Additional $150 Mil..
2020BioPharma Credit PLC with BioPharma Credit Investments V LP Enter into an Amended and R..
2020EPIZYME: Slumps 22% After Mixed Q3 Performance
1  2  3  4  5  6Pross.
Prossimo evento su EPIZYME, INC.
03/11/21